Table 1.
Baseline characteristic | Incident SCLC cases (N = 2938) | |
---|---|---|
Sex | n | % |
Male | 1524 | 51.9 |
Female | 1414 | 48.1 |
Age (years) | ||
Mean (±SD) | 68.45 (68.10–68.80) | |
50–59 | 94 | 3.2 |
60–69 | 451 | 15.4 |
70–79 | 972 | 33.1 |
80–89 | 1054 | 35.9 |
Smokinga | ||
Non-smoker | 141 | 4.8 |
Current | 1455 | 49.5 |
Former | 1299 | 44.2 |
Unknown | 43 | 1.5 |
BMI (kg/m2)a | ||
15–19 | 189 | 6.4 |
20–24 | 945 | 32.2 |
25–29 | 926 | 31.5 |
≥30 | 590 | 20.1 |
Unknown | 288 | 9.8 |
Alcohol (units/week)a | ||
None | 18,790 | 16.5 |
1–9 | 47,121 | 41.4 |
10–20 | 14,390 | 12.6 |
21–41 | 4986 | 4.4 |
≥42 | 1820 | 1.6 |
Unknown | 26,833 | 23.6 |
Geographical setting | ||
Urban | 1923 | 65.5 |
Town | 303 | 10.3 |
Rural | 113 | 3.8 |
Unknown | 599 | 20.4 |
Comorbiditiesb | ||
MI | 285 | 9.7 |
IS | 153 | 5.2 |
PAD | 289 | 9.8 |
Heart failure | 152 | 5.2 |
Hypertension | 1256 | 42.8 |
Hyperlipidaemia | 646 | 22.0 |
Dyspepsia | 789 | 26.9 |
Depression | 847 | 28.8 |
GERD | 531 | 18.1 |
Asthma | 718 | 24.4 |
COPD | 739 | 25.2 |
Medicationsc | ||
Beta2-agonists | 1181 | 40.2 |
Oral corticosteroids | 849 | 28.9 |
Inhaled steroids | 624 | 21.2 |
Antiplatelets | 1097 | 37.3 |
NSAIDs | 810 | 27.6 |
Opioids | 1604 | 54.6 |
PPIs | 1125 | 38.3 |
H2RA | 232 | 7.9 |
aEver before SCLC diagnosis using the most recent value/status as appropriate
bEver before SCLC diagnosis
cIn the year prior to SCLC diagnosis
BMI body mass index, COPD chronic obstructive pulmonary disease, DVT deep vein thrombosis, GERD gastro-oesophageal reflux disease, H2RA histamine 2 receptor antagonists, IS ischaemic stroke, MI myocardial infarction, NSAID non-steroidal anti-inflammatory drug, PAD peripheral artery disease, PPI proton pump inhibitor, SCLC small-cell lung cancer, SD standard deviation, TIA transient ischaemic attack